This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have received at least one dose of algenpantucel-L.
Study Type
OBSERVATIONAL
Enrollment
29
Cedars-Sinai Medical Center
Los Angeles, California, United States
Stanford University Cancer Center
Palo Alto, California, United States
Proportion of subjects with adverse events.
Time frame: Up to 15 years
Survival
Time frame: Up to 15 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
UF Health Cancer Center
Gainesville, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Northwestern University
Chicago, Illinois, United States
NorthShore University HealthSystem
Evanston, Illinois, United States
Indiana University Health Goshen Center for Cancer Care
Goshen, Indiana, United States
University of Louisville
Louisville, Kentucky, United States
Washington University
St Louis, Missouri, United States
Oregon Health and Science University
Portland, Oregon, United States
...and 5 more locations